Health News
An influential Lords Committee have today reported that a new and potentially deadly infectious disease emerges somewhere in the world every year and it is vital that there is more investment in international surveillance if pandemics are to be avoided.
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using a proprietary electroporation-based DNA delivery platform, announced recently pre-clinical results from two proprietary plasmid DNA-based universal influenza vaccine candidates using the company's proprietary electroporation delivery technology and, specifically, a new intradermal device.
Vical Incorporated (Nasdaq: VICL) announced a breakthrough with preliminary clinical trial data demonstrating that DNA vaccines can safely achieve significant immune responses against H5N1 pandemic influenza in humans.
Information relevant to Indiana's current pandemic influenza preparedness plan was presented July 16 during a symposium convened by the Indiana State Department of Health and the Indiana University Center for Bioethics, "The Ethics of Pandemic Influenza Planning in Indiana: What Have We Done and
New evidence suggests that a booster vaccination against H5N1 avian influenza given years after initial vaccination with a different strain may prove useful in controlling a potential future pandemic. The study is published in the August 1 issue of The Journal of Infectious Diseases, now available online. H5N1 continues to pose a major health risk to birds and humans.
Scientists and researchers have taken a big step closer to a cure for the most common strain of avian influenza, or "bird flu," the potential pandemic that has claimed more than 200 lives and infected nearly 400 people in 14 countries since it was identified in 2003. Researchers at the U.S.
Vical Incorporated (Nasdaq: VICL) announced the scheduled presentation of preliminary human safety and immunogenicity data from a Phase 1 trial of the company's Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccines on Thursday, July 17, at the IBC Life Sciences Next Generation Vaccines conference (National Harbor, MD - July 17-18). Vical's Vice President of Vaccine Research, Larry R. Smith, Ph.D.
Home Health Care During an Influenza Pandemic: Issues and Resources, a report identifying home health care as a critical component in providing care during a pandemic influenza event and offering resources to home health care providers and community planners to prepare for such an event, was released today by the U.S.
As the specter of a worldwide outbreak of avian or "bird flu" lingers, health officials recognize that new drugs are desperately needed since some strains of the virus already have developed resistance to the current roster of anti-flu remedies.
Researchers at the University of Pennsylvania School of Medicine have identified a potential new way to vaccinate against avian flu. By delivering vaccine via DNA constructed to build antigens against flu, along with a minute electric pulse, researchers have immunized experimental animals against various strains of the virus. This approach could allow for the build up of vaccine reserves that could be easily and effectively dispensed in case of an epidemic.